Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Oct 31, 2025 | (Q2)Jul 31, 2025 | (Q1)Apr 30, 2025 | (FY)Jan 31, 2025 | (Q4)Jan 31, 2025 | (Q3)Oct 31, 2024 | (Q2)Jul 31, 2024 | (Q1)Apr 30, 2024 | (FY)Jan 31, 2024 | (Q4)Jan 31, 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Cost of revenue | -71.05%9.5K | -69.57%124.49K | -44.61%124.49K | 0 | 0 | 20.65%32.81K | 409.05K | 224.74K | ||
| Gross profit | 71.05%-9.5K | 69.57%-124.49K | 44.61%-124.49K | 0 | 0 | -20.65%-32.81K | -409.05K | -224.74K | ||
| Operating expense | -80.09%18.51K | -92.30%56.33K | 74.10%44.93K | -22.51%806.41K | 60.62%-77.06K | -87.54%92.95K | 278.81%731.9K | -91.32%25.81K | 121.45%1.04M | -192.11%-195.68K |
| Selling and administrative expenses | -80.51%6.34K | 152.66%39.89K | 103.31%40.81K | -74.65%91.88K | 3,045.83%1.51K | -77.62%32.51K | -85.19%15.79K | -81.17%20.07K | 26.62%362.47K | -99.96%48 |
| -Selling and marketing expense | --0 | --705 | ---- | --0 | --0 | --0 | --0 | --0 | 680.61%52.87K | --0 |
| -General and administrative expense | -80.51%6.34K | 148.19%39.18K | 103.31%40.81K | -70.32%91.88K | 3,045.83%1.51K | -72.77%32.51K | -82.48%15.79K | -79.11%20.07K | 10.77%309.6K | -99.96%48 |
| Research and development costs | --0 | --0 | ---- | 1.71%675K | --0 | --0 | --675K | --0 | --663.64K | --21.25K |
| Other operating expenses | -79.86%12.17K | -60.01%16.44K | -28.11%4.12K | 172.11%39.54K | 63.79%-78.57K | 4.08%60.44K | -52.53%41.12K | -93.69%5.74K | -92.09%14.53K | -360.95%-216.98K |
| Operating profit | 80.09%-18.51K | 92.30%-56.33K | 7.15%-54.43K | 35.79%-930.9K | -63.20%-47.43K | 88.88%-92.95K | -181.62%-731.9K | 81.94%-58.62K | -208.50%-1.45M | 86.32%-29.06K |
| Net non-operating interest income (expenses) | ||||||||||
| Other net income (expenses) | -124.33%-486.19K | 1,263.29%236.01K | 160.04%17.8K | -135.25%-254K | -121.85%-24.93K | -236.13%-216.73K | -96.64%17.31K | -151.27%-29.65K | 120.86%720.47K | 98.82%-11.24K |
| Gain on sale of security | -75.13%-379.57K | 1,366.80%253.93K | 160.04%17.8K | -132.45%-254K | -121.85%-24.93K | -236.13%-216.73K | -96.83%17.31K | -133.44%-29.65K | 126.35%782.78K | 97.61%-11.24K |
| Income before tax | -62.97%-504.7K | 125.15%179.68K | 58.50%-36.63K | -62.49%-1.18M | -79.55%-72.36K | 54.25%-309.68K | -380.47%-714.59K | 66.92%-88.26K | 81.42%-729.22K | 96.55%-40.3K |
| Income tax | ||||||||||
| Earnings from equity interest net of tax | ||||||||||
| Net income | -62.97%-504.7K | 125.15%179.68K | 58.50%-36.63K | -62.49%-1.18M | -79.55%-72.36K | 54.25%-309.68K | -380.47%-714.59K | 66.92%-88.26K | 81.42%-729.22K | 96.55%-40.3K |
| Net income continuous operations | -62.97%-504.7K | 125.15%179.68K | 58.50%-36.63K | -62.49%-1.18M | -79.55%-72.36K | 54.25%-309.68K | -380.47%-714.59K | 66.92%-88.26K | 81.42%-729.22K | 96.55%-40.3K |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | -62.97%-504.7K | 125.15%179.68K | 58.50%-36.63K | -62.49%-1.18M | -79.55%-72.36K | 54.25%-309.68K | -380.47%-714.59K | 66.92%-88.26K | 81.42%-729.22K | 96.55%-40.3K |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | ||||||||||
| Net income attributable to common stockholders | -62.97%-504.7K | 125.15%179.68K | 58.50%-36.63K | -62.49%-1.18M | -79.55%-72.36K | 54.25%-309.68K | -380.47%-714.59K | 66.92%-88.26K | 81.42%-729.22K | 96.55%-40.3K |
| Diluted earnings per share | 0.00%-0.01 | 0 | 0 | -51.30%-0.02 | 0 | 18.51%-0.01 | -380.45%-0.013 | 66.91%-0.0016 | 81.42%-0.0132 | 96.55%-0.0007 |
| Basic earnings per share | 0.00%-0.01 | 0 | 0 | -51.30%-0.02 | 0 | 18.51%-0.01 | -380.45%-0.013 | 66.91%-0.0016 | 81.42%-0.0132 | 96.55%-0.0007 |
| Dividend per share | ||||||||||
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.